Phase I/II trial of high-dose radioimmunotherapy with a 90Y-humanized MN-14 anti-carcinoembroygenic antigen antibody (CEA) [labetuzumab Y-90] for the treatment of stage IV breast cancer
Phase of Trial: Phase I/II
Latest Information Update: 21 Jun 2011
At a glance
- Drugs Labetuzumab Y-90 (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- 30 Sep 2005 New trial record.